FMR1 and fragile X-associated tremor/ataxia syndrome: Decreased oleamide plasma levels were reported in FMR1 premutation carriers and proposed as a potential biomarker for the diagnosis of FXTAS [21], showing a negative correlation with CGG expansion [4], which was also identified in our analysis.